Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice

Vaccine

Volumn 31, Issue 46, 2013, Pages 5451-5457

  Rossi, Raffaella ^a   Granoff, Dan M ^a   Beernink, Peter T ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Animal model; Bactericidal; FH; FHbp; Mutant fHbp vaccine; Sub family A; Variant group 2

Indexed keywords

COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BINDING AFFINITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CROSS REACTION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOCIATION CONSTANT; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOGENICITY; ION EXCHANGE CHROMATOGRAPHY; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM BACTERICIDAL ACTIVITY; SERUM BACTERICIDAL ANTIBODY ASSAY; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; THERMOSTABILITY; TRANSITION TEMPERATURE; WILD TYPE;

ANIMAL MODEL; BACTERICIDAL; FH; FHBP; MUTANT FHBP VACCINE; SUB-FAMILY A; VARIANT GROUP 2;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MENINGOCOCCAL VACCINES; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; PROTEIN BINDING;

EID: 84886094710     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.099     Document Type: Article

References (32)

1. Granoff D.M. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease. Pediatr Infect Dis J 2013, 32(4):372-373.
2. Marshall H.S., Richmond P.C., Nissen M.D., Jiang Q., Anderson A.S., Jansen K.U., et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012, 31(10):1061-1068.
3. Richmond P.C., Marshall H.S., Nissen M.D., Jiang Q., Jansen K.U., Garces-Sanchez M., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases 2012, 12(8):597-607.
4. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
5. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
6. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
7. Welsch J.A., Ram S., Koeberling O., Granoff D.M. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008, 197(7):1053-1061.
8. Giuntini S., Reason D.C., Granoff D.M. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 2011, 79(9):3751-3759.
9. Konar M., Granoff D.M., Beernink P.T. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis 2013, 208(4):627-636.
10. Meri S., Jordens M., Jarva H. Microbial complement inhibitors as vaccines. Vaccine 2008, 26(Suppl. 8):I113-I117.
11. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009, 77(2):764-769.
12. Beernink P.T., Shaughnessy J., Braga E.M., Liu Q., Rice P.A., Ram S., et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 2011, 186(6):3606-3614.
13. Beernink P.T., Shaughnessy J., Pajon R., Braga E.M., Ram S., Granoff D.M. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog 2012, 8(5):e1002688.
14. Johnson S., Tan L., van der Veen S., Caesar J., Goicoechea De Jorge E., Harding R.J., et al. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog 2012, 8(10):e1002981.
15. Ufret-Vincenty R.L., Aredo B., Liu X., McMahon A., Chen P.W., Sun H., et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Invest Ophthalmol Vis Sci. 2010, 51(11):5878-5887.
16. Pajon R., Beernink P.T., Granoff D.M. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun 2012, 80(8):2667-2677.
17. Heger A., Kannicht C., Romisch J., Svae T.E. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox sanguinis 2007, 92(3):206-212.
18. Hakobyan S., Harris C.L., Tortajada A., Goicochea de Jorge E., Garcia-Layana A. Fernandez-Robredo P, et al. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008, 49(5):1983-1990.
19. Reynolds R., Hartnett M.E., Atkinson J.P., Giclas P.C., Rosner B., Seddon J.M. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci. 2009, 50(12):5818-5827.
20. Ingram G., Hakobyan S., Hirst C.L., Harris C.L., Pickersgill T.P., Cossburn M.D., et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010, 133(Pt. 6):1602-1611.
21. Beernink P.T., Welsch J.A., Bar-Lev M., Koeberling O., Comanducci M., Granoff D.M. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 2008, 76(9):4232-4240.
22. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., et al. Protein identification and analysis tools on the ExPASy server. The Proteomics Protocols Handbook 2005, 571-607. Humana Press Inc, New York, NY. J.M. Walker (Ed.).
23. Beernink P.T., Caugant D.A., Welsch J.A., Koeberling O., Granoff D.M. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009, 199(9):1360-1368.
24. Beernink P.T., Leipus A., Granoff D.M. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 2006, 13(7):758-763.
25. Pajon R., Fergus A.M., Koeberling O., Caugant D.A., Granoff D.M. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011, 5(9):e1302.
26. Mascioni A., Bentley B.E., Camarda R., Dilts D.A., Fink P., Gusarova V., et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 2009, 284(13):8738-8746.
27. Beernink P.T., LoPasso C., Angiolillo A., Felici F., Granoff D. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol 2009, 46(8-9):1647-1653.
28. Granoff D.M., Ram S., Beernink P.T. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?. Clin Vaccine Immunol 2013, 20(8):1099-1107.
29. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28(9):2122-2129.
30. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., MacNeil J.R., et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, 29(29-30):4739-4744.
31. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):379-389.
32. Granoff D.M., Bartoloni A., Ricci S., Gallo E., Rosa D., Ravenscroft N., et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998, 160(10):5028-5036.